Proteomics diagnostic tests shift from lab coats to commercial launch
Proteomics International Laboratories is transitioning from research to commercial operations with a new suite of diagnostic tests. The company aims to leverage distribution partners to enhance market acceptance and efficiency. Their initial offerings include tests for kidney disease, cancer, and endometriosis, targeting significant patient populations in Australia and the US.
- ▪Proteomics International is launching a four-test diagnostics suite targeting kidney disease, cancer, and endometriosis.
- ▪The company is adopting a distribution partner model to reduce costs and improve market entry.
- ▪PromarkerD is a leading test that predicts diabetes-related chronic kidney disease up to four years before symptoms appear.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","dateModified":"2026-04-28T07:02:57Z","datePublished":"2026-04-28T07:02:57Z","description":"Proteomics International is rolling out a commercial roadmap with a four-test diagnostics suite targeting kidney disease, cancer and endometriosis across Australia and the US.","headline":"Proteomics diagnostic tests shift from lab coats to commercial launch","keywords":"Bulls N' Bears, Shares, Sharemarket","author":[{"@type":"Person","name":"Doug…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Sydney Morning Herald.